Literature DB >> 21387535

In-hospital outcomes of very elderly patients (85 years and older) undergoing percutaneous coronary intervention.

Clare E Appleby1, Joan Ivanov, Karen Mackie, Vladimír Džavík, Christopher B Overgaard.   

Abstract

OBJECTIVE: To compare in-hospital outcomes of a large cohort of very elderly patients (age ≥ 85 years) with younger patients (age < 85 years) undergoing percutaneous coronary intervention (PCI) for all indications at our institution.
BACKGROUND: Interventionist cardiologists are often reluctant to undertake PCI in very elderly patients due to the perception of poor outcome in this high-risk cohort. However, the prognostic significance of advanced age itself is not clear.
METHODS: Baseline clinical, angiographic and procedural variables, and in-hospital outcome data were entered into a prospective registry of 17,572 consecutive patients undergoing PCI at the University Health Network between April 2000 and December 2008. Patients were stratified according to age (< 85 years, n = 17,168, or ≥ 85 years, n = 404) and in-hospital mortality, major adverse cardiac events (MACE), and complication rates were calculated. Logistic regression-analysis identified independent predictors of unadjusted mortality and MACE. Very elderly patients were propensity matched with younger patients (1:2 ratio), and the analysis repeated.
RESULTS: Very elderly patients had a mean age of 87.5 ± 2.9 (range, 85-97 years) vs. 62.8 ± 11.1 years for the younger cohort and had a greater number of comorbid conditions. This cohort were more likely to present as an urgent or primary PCI, underwent more complex interventions, and achieved less angiographic success. Unadjusted mortality and post procedure myocardial infarction were significantly higher in very elderly patients (6.93% vs. 1.20%, P < 0.0001 and 4.46% vs. 2.74%, P = 0.04). Renal, neurological, and access-site complications were all greater in the very elderly cohort. Although age ≥ 85 years was a significant independent predictor of both mortality (OR, 2.62; CI, 1.44-4.78, P = 0.0016) and MACE (OR, 1.94; CI, 1.25-3.01, P = 0.003), other variables such as cardiogenic shock were more potent predictors of adverse outcomes.
CONCLUSION: Very elderly patients represent a high-risk cohort, with significantly increased in-hospital mortality and complication rates after PCI. Death occurred predominantly in very elderly patients undergoing nonelective PCI. Decisions to proceed with PCI in very elderly patients should be based on other prognostic variables in combination with advanced age, and these patients should not be excluded from revascularization based on age alone.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21387535     DOI: 10.1002/ccd.22729

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  Second-generation drug-eluting stents in the elderly patients with acute coronary syndrome: the in-hospital and 12-month follow-up of the all-comer registry.

Authors:  Wojciech Wańha; Damian Kawecki; Tomasz Roleder; Beata Morawiec; Sylwia Gładysz; Adam Kowalówka; Tomasz Jadczyk; Barbara Adamus; Tomasz Pawłowski; Grzegorz Smolka; Maciej Kaźmierski; Andrzej Ochała; Ewa Nowalany-Kozielska; Wojciech Wojakowski
Journal:  Aging Clin Exp Res       Date:  2016-11-10       Impact factor: 3.636

2.  Elderly Suffering from ST-Segment Elevation Myocardial Infarction-Results from a Database Analysis from Two Mediterranean Medical Centers.

Authors:  Leor Perl; Alfonso Franzé; Fabrizio D'Ascenzo; Noa Golomb; Amos Levi; Hana Vaknin-Assa; Gabriel Greenberg; Abid Assali; Gaetano M De Ferrari; Ran Kornowski
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

3.  Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality.

Authors:  Salim Bary Barywani; Shijun Li; Maria Lindh; Josefin Ekelund; Max Petzold; Per Albertsson; Lars H Lund; Michael Lx Fu
Journal:  Clin Interv Aging       Date:  2015-09-28       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.